CLINICAL TRIALS PROFILE FOR SODIUM BENZOATE; SODIUM PHENYLACETATE
✉ Email this page to a colleague
All Clinical Trials for sodium benzoate; sodium phenylacetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004767 ↗ | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | Johns Hopkins University | Phase 2 | 1985-01-01 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00004767 ↗ | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | National Center for Research Resources (NCRR) | Phase 2 | 1985-01-01 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00597909 ↗ | Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | Terminated | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 2 | 2007-12-01 | The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE). |
| NCT00977600 ↗ | A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | Completed | Ucyclyd Pharma, Inc. | Phase 1 | 2005-03-01 | To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects. |
| NCT00977600 ↗ | A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 1 | 2005-03-01 | To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sodium benzoate; sodium phenylacetate
Condition Name
Condition MeSH
| Condition MeSH for sodium benzoate; sodium phenylacetate | |
| Intervention | Trials |
| Urea Cycle Disorders, Inborn | 1 |
| Metabolism, Inborn Errors | 1 |
| Amino Acid Metabolism, Inborn Errors | 1 |
| Hepatic Encephalopathy | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for sodium benzoate; sodium phenylacetate
Trials by Country
Clinical Trial Progress for sodium benzoate; sodium phenylacetate
Clinical Trial Phase
Clinical Trial Sponsors for sodium benzoate; sodium phenylacetate
Sponsor Name
